Helft, G.Worthley, S.2007-10-162007-10-162001Heart Lung and Circulation, 2001; 10(2):68-741443-9506http://hdl.handle.net/2440/39093The definitive version is available at www.blackwell-synergy.comSignificant advances in the treatment of patients with acute myocardial infarction (MI) have been obtained in recent times. In particular, thrombolytic therapy has been shown to preserve ventricular function and improve survival in patients with acute MI. Therapies now include third-generation thrombolytic agents, percutaneous transluminal coronary angioplasty (PTCA) and intracoronary stenting, and new anti-thrombotic therapies including anti-platelet treatment with glycoprotein (GP) IIb/IIIa inhibition and direct anti-thrombin agents. This review will focus on the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to thrombolytic treatment of patients with acute MI.enanti-thrombotic therapymyocardial infarctionthrombosisJournal article002007203510.1046/j.1444-2892.2001.00086.x2-s2.0-003515820647955